Transforming the lives of airways disease patients

Vectura is a FTSE 250, industry-leading device & formulation business for inhaled airways disease.

 

Background

  • Recurring revenues driven by on-market partnered products, underpinned by a robust pipeline
  • Consilium appointed to provide strategic IR and communications guidance to enlarged Vectura Group post-merger with Skyepharma in 2016

£441m

merger with Skyepharma

 

Our strategy

  • Supporting implementation of international IR and profile raising strategy
  • Review of corporate materials including website, key messaging, presentation, Q&A
  • Immediate media engagement to position Vectura as new international ‘respiratory powerhouse’
  • Initiated introductions to expand high quality sell-side analyst coverage

 

Outcome

  • Increased visibility in business, investor and trade media internationally including The Times, The Wall Street Journal, the Financial Times, The Daily Telegraph and Reuters
  • Significant interest from international analysts, media and investors channelled through Consilium
  • Simplification of investment case – enhanced focus on core strengths and clear guidance